Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 10/2009

01-10-2009 | Article

Insulin resistance, beta cell dysfunction and visceral adiposity as predictors of incident diabetes: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study

Authors: A. J. G. Hanley, L. E. Wagenknecht, J. M. Norris, M. Bryer-Ash, Y. I. Chen, A. M. Anderson, R. Bergman, S. M. Haffner

Published in: Diabetologia | Issue 10/2009

Login to get access

Abstract

Aims/hypothesis

Central obesity, insulin resistance and beta cell dysfunction are independent risk factors for incident type 2 diabetes, although few studies have used detailed measures of these disorders. Our objective was to study the association of directly measured visceral and subcutaneous adipose tissue (VAT, SAT), insulin sensitivity (S I) and the acute insulin response (AIR) with incident type 2 diabetes.

Methods

Participants were 1,230 Hispanic-Americans and African-Americans in the Insulin Resistance Atherosclerosis Study (IRAS) Family Study who were free of type 2 diabetes at baseline (2000–2002). S I and AIR were determined from frequently sampled IVGTTs with minimal model analysis. VAT and SAT were determined by computed tomography. Impaired fasting glucose and type 2 diabetes were defined according to American Diabetes Association criteria.

Results

Incident type 2 diabetes was diagnosed in 90 participants after 5 years. After adjustment for age, sex, ethnicity, centre, impaired fasting glucose, triacylglycerol, HDL-cholesterol and systolic BP, both SI and AIR were inversely associated with type 2 diabetes (S I, OR 0.53, 95% CI 0.39–0.73; AIR, OR 0.22, 95% CI 0.14–0.34 per SD; both p < 0.001), while both VAT and SAT were positively associated with type 2 diabetes (VAT, OR 1.68, 95% CI 1.22–2.33; SAT, OR 1.49, 95% CI 1.13–1.99; both p < 0.01). In a model including all four factors, S I and AIR (S I, OR 0.55, 95% CI 0.37–0.80; AIR, OR 0.21, 95% CI 0.13–0.33; both p < 0.01) were significant predictors of type 2 diabetes, although associations with VAT and SAT were no longer significant. A significant sex × VAT interaction indicated a stronger association of VAT with type 2 diabetes in women than in men.

Conclusions/interpretation

Insulin resistance, beta cell dysfunction and VAT predicted incident type 2 diabetes, with evidence of a stronger association of VAT with type 2 diabetes among women.
Literature
1.
Carey VJ, Walters EE, Colditz GA et al (1997) Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses Health Study. Am J Epidemiol 145:614–619PubMed
2.
Folsom AR, Kushi LH, Anderson KE et al (2000) Associations of general and abdominal obesity with multiple health outcomes in older women: the Iowa Women's Health Study. Arch Intern Med 160:2117–2128PubMedCrossRef
3.
Ohlson LO, Larsson B, Svardsdudd K (1985) The influence of body fat distribution on the incidence of diabetes mellitus: 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes 34:1055–1058PubMedCrossRef
4.
Wang Y, Rimm EB, Stampfer MJ, Willet WC, Hu FB (2005) Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr 81:555–563PubMed
5.
6.
Jensen MD (2006) Is visceral fat involved in the pathogenesis of the metabolic syndrome? Human model. Obesity (Silver Spring) 14(Suppl 1):20S–24SCrossRef
7.
Bergman RN, Kim SP, Hsu IR et al (2007) Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. Am J Med 120(2 Suppl 1):S3–S8, discussion S29–S32PubMedCrossRef
8.
Atzmon G, Yang XM, Muzumdar R, Ma XH, Gabriely I, Barzilai N (2002) Differential gene expression between visceral and subcutaneous fat depots. Horm Metab Res 34:622–628PubMedCrossRef
9.
Iacobellis G (2005) Imaging of visceral adipose tissue: an emerging diagnostic tool and therapeutic target. Curr Drug Targets Cardiovasc Haematol Disord 5:345–353PubMedCrossRef
10.
Hanley AJG, Wagenknecht LE (2008) Abdominal adiposity and diabetes risk: the importance of precise measures and longitudinal studies (invited commentary). Diabetes 57:1153–1155PubMedCrossRef
11.
Wagenknecht L, Langefield C, Scherzinger A, Norris J et al (2003) Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin resistance Atherosclerosis Study (IRAS) Family Study. Diabetes 52:2490–2496PubMedCrossRef
12.
Fox CS, Massaro JM, Hoffmann U et al (2007) Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 116:39–48PubMedCrossRef
13.
Pou KM, Massaro JM, Hoffman U et al (2007) Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation 116:1234–1241PubMedCrossRef
14.
Boyko EJ, Fujimoto WY, Leonetti DL, Newell-Morris L (2000) Visceral adiposity and risk of type 2 diabetes. A prospective study among Japanese Americans. Diabetes Care 23:465–471PubMedCrossRef
15.
Kanaya AM, Wassel Fyr C, Vittinghoff E et al (2006) Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1. Arch Intern Med 166:350–356PubMedCrossRef
16.
Henkin L, Bergman RN, Bowden DW et al (2003) Genetic epidemiology of insulin resistance and visceral adiposity: the IRAS Family Study Design and Methods. Ann Epidemiol 13:211–217PubMedCrossRef
17.
Hanley AJG, Bowden D, Wagenknecht LE et al (2007) Associations of adiponectin with body fat distribution and insulin sensitivity in non-diabetic Hispanic and African Americans. J Clin Endocrinol Metab 92:2665–2671PubMedCrossRef
18.
Bergman RN, Finegood DT, Ader M (1985) Assessment of insulin sensitivity in vivo. Endocrine Rev 6:45–86CrossRef
19.
Welch S, Gebhart SSP, Bergman RN, Phillips LS (1990) Minimal model analysis of intravenous glucose tolerance test derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab 71:1508–1518PubMedCrossRef
20.
Steil GM, Volund A, Kahn SE, Bergman RN (1993) Reduced sample number for calculation of insulin sensitivity and glucose effectiveness from the minimal model: suitability for use in population studies. Diabetes 42:250–256PubMedCrossRef
21.
Pacini G, Bergman RN (1986) MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed 23:113–122PubMedCrossRef
22.
Bergman RN, Finegood DT, Kahn SE (2002) The evolution of beta cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 32(Suppl 3):35–45PubMedCrossRef
23.
Herbert V, Lau K, Gottlieb C, Bleicher S (1965) Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 25:1375–1384PubMedCrossRef
24.
Albu JB, Murphy L, Frager DH, Johnson JA, Pi-Sunyer F (1997) Visceral fat and race-dependent health risks in obese nondiabetic premenopausal women. Diabetes 46:456–462PubMedCrossRef
25.
Hill JO, Sidney S, Lewis CE, Tolan K, Scherzinger AL, Stamm ER (1999) Racial differences in amounts of visceral adipose tissue in young adults: the CARDIA (Coronary Artery Risk Development in Young Adults) Study. Am J Clin Nutr 69:381–387PubMed
26.
Macor C, Ruggeri A, Mazzonetto P, Federspil G, Cobelli C, Vettor R (1997) Visceral adipose tissue impairs insulin secretion and insulin sensitivity but not energy expenditure in obesity. Metabolism 46:123–129PubMedCrossRef
27.
Hayashi T, Boyko EJ, Leonetti DL et al (2003) Visceral adiposity and the risk of impaired glucose tolerance: a prospective study among Japanese Americans. Diabetes Care 26:650–655PubMedCrossRef
28.
Kanaya AM, Harris T, Goodpaster BH, Tylavsky F, Cummings SR, Health, Aging, and Body Composition (ABC) Study (2004) Adipocytokines attenuate the association between visceral adiposity and diabetes in older adults. Diabetes Care 27:1375–1380PubMedCrossRef
29.
Nicklas BJ, Penninx BW, Cesari M et al (2004) Association of visceral adipose tissue with incident myocardial infarction in older men and women: the Health, Aging and Body Composition Study. Am J Epidemiol 160:741–749PubMedCrossRef
30.
Weyer C, Bogardus C, Mott DM, Pratley RE (1999) The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787–794PubMedCrossRef
31.
Lillioja S, Mott DM, Spraul M et al (1993) Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 329:1988–1992PubMedCrossRef
32.
Warram JH, Sigal RJ, Martin BC, Krolewski AS, Soeldner JS (1996) Natural history of impaired glucose tolerance: follow-up at Joslin Clinic. Diabetes Med 13(Suppl 6):S40–S45
33.
Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR (1992) Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 340:925–929PubMedCrossRef
34.
Hanley AJG, D'Agostino R Jr, Wagenknecht LE et al (2002) Increased proinsulin levels and decreased acute insulin response independently predict the incidence of type 2 diabetes in the Insulin Resistance Atherosclerosis Study. Diabetes 51:1263–1270PubMedCrossRef
Metadata
Title
Insulin resistance, beta cell dysfunction and visceral adiposity as predictors of incident diabetes: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study
Authors
A. J. G. Hanley
L. E. Wagenknecht
J. M. Norris
M. Bryer-Ash
Y. I. Chen
A. M. Anderson
R. Bergman
S. M. Haffner
Publication date
01-10-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1464-y

Other articles of this Issue 10/2009

Diabetologia 10/2009 Go to the issue

Article

Is islet autoimmunity related to insulin sensitivity or body weight in children of parents with type 1 diabetes?

Article

Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial

Article

Regulation of skeletal muscle sucrose, non-fermenting 1/AMP-activated protein kinase-related kinase (SNARK) by metabolic stress and diabetes

Article

A variant in the G6PC2/ABCB11 locus is associated with increased fasting plasma glucose, increased basal hepatic glucose production and increased insulin release after oral and intravenous glucose loads

Article

C-peptide is internalised in human endothelial and vascular smooth muscle cells via early endosomes

Article

Long-term effect of modification of dietary protein intake on the progression of diabetic nephropathy: a randomised controlled trial
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits